• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Rocket Pharmaceuticals Inc (NQ: RCKT )

    25.33 -0.55 (-2.13%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 821,175
    Open 26.45
    Bid (Size) 24.50 (1)
    Ask (Size) 27.20 (1)
    Prev. Close 25.88
    Today's Range 25.33 - 26.98
    52wk Range 14.89 - 32.52
    Shares Outstanding 65,837,894
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides
    Rocket Pharmaceuticals shares fell after the FDA issued a Complete Response Letter for Kresladi, a gene therapy for severe leukocyte adhesion deficiency-I. The FDA requested additional CMC... 
    Via Benzinga
    Exposures Product Safety
    Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -14.14%
    -14.14%
    1 Month
    +6.21%
    +6.21%
    3 Month
    +14.62%
    +14.62%
    6 Month
    -10.90%
    -10.90%
    1 Year
    +46.25%
    +46.25%

    More News

    Read More
    Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
    Via Talk Markets
    Analyst Ratings for Rocket Pharmaceuticals
    Via Benzinga
    Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024
    Via InvestorPlace
    Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    7 Speculative Stocks to Double Your Money THIS Year
    Via InvestorPlace
    Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    Merit Medical Systems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    Rocket Pharmaceuticals Stock Sees Improved Price Strength
    Via Investor's Business Daily
    Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher
    Via Investor's Business Daily
    Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
    Via Benzinga
    Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference
    From Rocket Pharmaceuticals, Inc.
    Via Business Wire
    Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals
    Via The Motley Fool
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.